Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE4
Total Enrollment
70 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-08-01
Study Completion Date
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD). Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung.
This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of participants will be enrolled remotely via telemedicine utilizing certified mobile home research nurses and various remote monitoring devices.
The research visits may include a physical exam, vital signs (such as blood pressure, heart rate, etc.), pulmonary function tests (PFT and/or home spirometry), Computerized Tomography (or CT) scans of the chest, blood draws, wearing a physical activity monitor and completing questionnaires. Some of these events may be done at home, at a local facility or remotely (via telemedicine).
This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of participants will be enrolled remotely via telemedicine utilizing certified mobile home research nurses and various remote monitoring devices.
The research visits may include a physical exam, vital signs (such as blood pressure, heart rate, etc.), pulmonary function tests (PFT and/or home spirometry), Computerized Tomography (or CT) scans of the chest, blood draws, wearing a physical activity monitor and completing questionnaires. Some of these events may be done at home, at a local facility or remotely (via telemedicine).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease
NCT05335278
Interstitial Lung Disease
Myopathy, Inflammatory
TERMINATED
NA
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
NCT05833711
Dermatomyositis
Polymyositis
Idiopathic Inflammatory Myopathies
UNKNOWN
PHASE2
Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells
NCT05129410
Idiopathic Inflammatory Myopathy
Interstitial Lung Disease
UNKNOWN
PHASE4
Immune Abnormalities in Sporadic Inclusion Body Myositis
NCT00030212
Sporadic
Inclusion Body
Myositis
COMPLETED
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167
Active Idiopathic Inflammatory Myopathy
Myositis
Dermatomyositis
+3 more
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants enrolled in the study will receive either study drug or placebo for 12 weeks plus the participant's normal standard of care medication for the participant's disease. Placebo is an inactive substance that contains no medicine. Following the initial treatment phase, participants will receive the active study drug (nintedanib) for an additional 12-week period.
Nintedanib is a drug that is currently used and has been approved by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), and has been shown to slow the rate of decline in pulmonary function among patients with IPF as well as interstitial lung disease (ILD) associated with systemic sclerosis or scleroderma. In addition, in March 2020, the FDA approved nintedanib oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).
Nintedanib is a drug that is currently used and has been approved by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), and has been shown to slow the rate of decline in pulmonary function among patients with IPF as well as interstitial lung disease (ILD) associated with systemic sclerosis or scleroderma. In addition, in March 2020, the FDA approved nintedanib oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Myositis Associated Interstitial Lund Disease (MA-ILD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Randomization will be 1:1 for nintedanib: placebo and stratified by underlying immunosuppressive therapy (mycophenolate vs. others). All patients must be on the standard of care (SOC) immunosuppression (IS) at screening as per the protocol and should remain on stable doses throughout the trial. After 12 weeks both arms will receive an additional 12 weeks of nintedanib (150 mg twice a day, maximum dose of 300 mg a day) through week 24 (final study visit).
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Subjects, investigators, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial will remain blinded with regard to the randomized treatment assignments until after the database lock.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo plus Standard of Care, then Nintedanib plus Standard of Care
Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
Group Type
PLACEBO_COMPARATOR
Nintedanib
Intervention Type
DRUG
Nintedanib 150 mg BID
Placebo
Intervention Type
DRUG
Placebo comparator
Standard of Care
Intervention Type
DRUG
Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
Nintedanib plus Standard of Care
Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
Group Type
ACTIVE_COMPARATOR
Nintedanib
Intervention Type
DRUG
Nintedanib 150 mg BID
Standard of Care
Intervention Type
DRUG
Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nintedanib
Nintedanib 150 mg BID
Intervention Type
DRUG
Placebo
Placebo comparator
Intervention Type
DRUG
Standard of Care
Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
OFEV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject has provided written informed consent
2. Approval from local treating physician (done at pre-screening only for remote patients as well as for local site patients not actively being managed at the local site).
3. Subject lives in the United States
4. Adult: Age ≥ 18 years
5. Subject can speak, read, and understand English or Spanish
6. Subject is willing and capable of performing all study procedures.
7. Validity/repeatability of home spirometry confirmed by PFT lab technician/MD through telemedicine as per American Thoracic Society guidelines.
8. Men and women of reproductive potential must agree to use 2 reliable methods of birth control during the trial period.
9. Clinical diagnosis of myositis or presence of one of the following myositis-specific or -associated autoantibodies).
1. Anti-synthetase autoantibody (Anti-Jo-1, -PL-7, -PL-12, -EJ, -OJ, -KS, -Tyr, -Zo)
2. Anti-MDA5, TIF1-gamma, Mi-2, NXP2/MJ, SAE, HMGCR, SRP
3. Anti-PM/Scl, Ku, U1RNP, Ro5,2/60, or SSA (in absence of clinical diagnosis of systemic sclerosis or primary Sjogren syndrome).
10. Fibrosing Interstitial Lung Disease (ILD):
1. HRCT chest within 12 months of screening visit with fibrosing ILD (reticular changes, traction bronchiectasis, and/or honeycombing)
2. No other identifiable cause of fibrosis
3. The following co-existing features are expected and accepted: ground glass opacity, upper lung or peri-bronchovascular predominance, mosaic attenuation, air trapping, consolidation, and centrilobular nodules.
11. Progressive ILD: Defined as meeting ≥1 of the following criteria within 24 months of the screening visit.
1. ≥10% relative decline in FVC% predicted (%pred)
2. ≥5 but \<10% relative decline in FVC %pred with worsening dyspnea.
3. ≥5 but \<10% relative decline in FVC %pred with worsening chest HRCT fibrotic changes
4. Worsening dyspnea with worsening chest HRCT fibrosis
5. Worsening dyspenea with FCV% \</= 70%
12. Standard of care (SOC) therapy: (See: SOC immunosuppression and washout under section 6.2 for details)
1. Allowable SOC includes a maximum of 2: 1 glucocorticoid (GC) and 1 Non-GC immunosuppressive medication (IS) Or 2 Non-GC immunosuppressive medications.
2. Allowable IS component of SOC regimen must have been started at least 12 weeks prior and be stable for at least 4 weeks before baseline visit.
3. In case a patient is not on any of the SOC immunosuppression, patient can be enrolled if at least 2 SOC immunosuppression are either previously failed or had intolerance or are contra-indicated.
4. Allowable GC component of SOC regimen must have been started at least 4 weeks prior and be stable for at least 2 weeks before baseline visit.
5. Allowable IS and GC:
Glucocorticoid (maximum dose ≤20 mg/day; prednisone equivalent). Mycophenolate mofetil (max dose 3 gm/day) Mycophenolic acid (max dose 2,160 mg/day) Azathioprine (max dose 2.5 mg/kg/day) Methotrexate (max dose 25 mg/week Tacrolimus (max dose 10 mg/day) Cyclosporine (max dose 200 mg/day) Leflunomide (max dose 20 mg/day) Sulfasalazine (max dose 3 gm/day) JAK inhibitors (tofacitinib max does 11 mg/day, upadacitinib max dose 15 mg/day, baricitinib max does 4 mg/day) IVIG (Intravenous immunoglobulin) or SQIG (subcutaneous immunoglobulin) (max dose 2 gm/kg/month) is allowed and not considered as SOC IS therapy Rituximab (maximum dose 1000 mg x 2 (2 weeks apart) or 375mg/m2 weekly dose x 4, repeated every \> 4 months) Hydroxychloroquine is allowed and not considered as SOC IS therapy. Orencia (max dose of 125 mg SQ once a week or 1 gm monthly IV infusion)
6. Inhaled medication(s) for lung disease is allowed if started \> 4 weeks before screening.
Should remain stable throughout the study.
13. Negative pregnancy test
2. Approval from local treating physician (done at pre-screening only for remote patients as well as for local site patients not actively being managed at the local site).
3. Subject lives in the United States
4. Adult: Age ≥ 18 years
5. Subject can speak, read, and understand English or Spanish
6. Subject is willing and capable of performing all study procedures.
7. Validity/repeatability of home spirometry confirmed by PFT lab technician/MD through telemedicine as per American Thoracic Society guidelines.
8. Men and women of reproductive potential must agree to use 2 reliable methods of birth control during the trial period.
9. Clinical diagnosis of myositis or presence of one of the following myositis-specific or -associated autoantibodies).
1. Anti-synthetase autoantibody (Anti-Jo-1, -PL-7, -PL-12, -EJ, -OJ, -KS, -Tyr, -Zo)
2. Anti-MDA5, TIF1-gamma, Mi-2, NXP2/MJ, SAE, HMGCR, SRP
3. Anti-PM/Scl, Ku, U1RNP, Ro5,2/60, or SSA (in absence of clinical diagnosis of systemic sclerosis or primary Sjogren syndrome).
10. Fibrosing Interstitial Lung Disease (ILD):
1. HRCT chest within 12 months of screening visit with fibrosing ILD (reticular changes, traction bronchiectasis, and/or honeycombing)
2. No other identifiable cause of fibrosis
3. The following co-existing features are expected and accepted: ground glass opacity, upper lung or peri-bronchovascular predominance, mosaic attenuation, air trapping, consolidation, and centrilobular nodules.
11. Progressive ILD: Defined as meeting ≥1 of the following criteria within 24 months of the screening visit.
1. ≥10% relative decline in FVC% predicted (%pred)
2. ≥5 but \<10% relative decline in FVC %pred with worsening dyspnea.
3. ≥5 but \<10% relative decline in FVC %pred with worsening chest HRCT fibrotic changes
4. Worsening dyspnea with worsening chest HRCT fibrosis
5. Worsening dyspenea with FCV% \</= 70%
12. Standard of care (SOC) therapy: (See: SOC immunosuppression and washout under section 6.2 for details)
1. Allowable SOC includes a maximum of 2: 1 glucocorticoid (GC) and 1 Non-GC immunosuppressive medication (IS) Or 2 Non-GC immunosuppressive medications.
2. Allowable IS component of SOC regimen must have been started at least 12 weeks prior and be stable for at least 4 weeks before baseline visit.
3. In case a patient is not on any of the SOC immunosuppression, patient can be enrolled if at least 2 SOC immunosuppression are either previously failed or had intolerance or are contra-indicated.
4. Allowable GC component of SOC regimen must have been started at least 4 weeks prior and be stable for at least 2 weeks before baseline visit.
5. Allowable IS and GC:
Glucocorticoid (maximum dose ≤20 mg/day; prednisone equivalent). Mycophenolate mofetil (max dose 3 gm/day) Mycophenolic acid (max dose 2,160 mg/day) Azathioprine (max dose 2.5 mg/kg/day) Methotrexate (max dose 25 mg/week Tacrolimus (max dose 10 mg/day) Cyclosporine (max dose 200 mg/day) Leflunomide (max dose 20 mg/day) Sulfasalazine (max dose 3 gm/day) JAK inhibitors (tofacitinib max does 11 mg/day, upadacitinib max dose 15 mg/day, baricitinib max does 4 mg/day) IVIG (Intravenous immunoglobulin) or SQIG (subcutaneous immunoglobulin) (max dose 2 gm/kg/month) is allowed and not considered as SOC IS therapy Rituximab (maximum dose 1000 mg x 2 (2 weeks apart) or 375mg/m2 weekly dose x 4, repeated every \> 4 months) Hydroxychloroquine is allowed and not considered as SOC IS therapy. Orencia (max dose of 125 mg SQ once a week or 1 gm monthly IV infusion)
6. Inhaled medication(s) for lung disease is allowed if started \> 4 weeks before screening.
Should remain stable throughout the study.
13. Negative pregnancy test
Exclusion Criteria
1. Planned major surgical procedures within the trial period of 24 weeks.
2. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
3. Women of childbearing potential\* not willing or able to use at least two highly effective methods of birth control.
1. For females of reproductive potential: use of highly effective contraception for at least 1 month before study drug administration and agreement to use such a method during study participation and for an additional 28 days after the end of study drug administration.
2. For males of reproductive potential\*\*: use of condoms or other methods to ensure effective contraception with a partner
Highly effective contraception examples are:
* An approved hormonal contraceptive such as oral contraceptives, emergency contraception used as directed, patches, implants, injections, rings, hormonally-impregnated intrauterine device (IUD), or nonhormonal IUD.
* Abstinence
* Condoms
* A woman is considered of childbearing potential, i.e. fertile, following menarche, and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, tubal occlusion, and bilateral oophorectomy.
* A man is considered permanently sterile if a vasectomy has been performed.
4. Severe lung disease is defined by the following within the last 6 months before the screening:
1. FVC ≤40 percent predicted
2. DLCO \<30% of percent predicted (corrected for Hb)
3. O2 requirement of ≥10 L at rest based on home oxygen prescription.
4. Patient listed for lung transplant or actively going through lung transplant evaluation.
5. Moderate to severe active muscle disease from myositis as per any one of the criteria:
1. Creatine kinase (CK) \> 2000 U/mL.
2. Moderate to severe dermatomyositis rashes as per investigator evaluation (if rash present)
3. Moderate to severe arthritis as per investigator evaluation
4. Moderate to severe muscle weakness as per Sit to Stand 30 seconds of \< 7.
6. History of or ongoing serious active, chronic, or recurrent infection within 4 weeks of screening
7. Significant Pulmonary Hypertension (PH) is defined by any of the following:
1. Current clinical diagnosis of moderate to severe PH or significant right heart failure.
2. History of echocardiographic evidence of significant right heart failure or moderate to severe PH (TR jet \>= 2.9 m/s and signs of right ventricle (RV) dysfunction; or TR jet \> 3.4; or an right ventricle systolic pressure (RVSP) \> 40-55 with evidence of RV strain or dysfunction; or RVSP \> 55 regardless.
3. History of right heart catheterization showing a cardiac index ≤ 2.2 l/min/m² or severity of pulmonary hypertension (mPAP) \>40 millimeters of mercury (mmHg) with a pulmonary capillary wedge pressure (PCWP) \<15mmHg
4. PH requiring oral, IV, or inhaled therapy (such as epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, sildenafil, and tadalafil).
8. Increased bleeding risk, defined by any of the following:
1. Patients who require
* Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, factor Xa inhibitors, low molecular weight heparin)
* High dose antiplatelet therapy (\>325mg acetylsalicylic acid or \>75mg clopidogrel).
2. History of hemorrhagic central nervous system (CNS) event within 12 months of screening.
3. Any of the following within 3 months of screening:
* Hemoptysis or hematuria
* Active gastrointestinal (GI) bleeding or active GI ulcers.
4. Coagulation parameters: International normalized ratio (INR) \>2, prolongation of prothrombin time (PT) and by \>1.5 x ULN at screening.
9. History of a thrombotic event (including stroke and transient ischemic attack) within 12 months of screening.
10. Severe Cardiovascular disease, any of the following:
1. Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 months of screening.
2. Myocardial infarction or unstable cardiac angina within 6 months of screening.
11. Patients with underlying chronic liver disease (Child-Pugh A, B, or C hepatic impairment).
12. Known hypersensitivity to the trial medication or its components (i.e. soya lecithin)
13. Other diseases that may interfere with testing procedures or in the judgment of the Investigator may interfere with trial participation (such as significant GI issues like irritable bowel syndrome, inflammatory bowel disease, recent abdominal surgery, diverticular disease), or significant other lung diseases (such as severe obstructive lung disease such as severe asthma or severe chronic obstructive pulmonary disease, etc.) or may put the patient at risk when participating in this trial.
14. Life expectancy for a disease other than ILD \< 2.5 years (Investigator assessment).
15. In the opinion of the investigator, any condition precluding participation and completion of the study, including active alcohol and drug abuse or patients not able to understand or follow trial procedures.
16. Other investigational therapy was received within 1 month or 6 half-lives (whichever was greater) before the screening visit.
17. Current treatment with nintedanib or pirfenidone (taken the drug within 3 months of randomization or history of intolerance/side effects)
18. Current or recent use of one or more of the following medications (See: SOC immunosuppression and washout under section 6.2 for details)
1. Cyclophosphamide within 3 months of baseline.
2. Anti-tumor necrosis factor (infliximab, golimumab, or certolizumab) within 8 weeks or adalimumab within 4 weeks, and etanercept within 2 weeks of baseline.
3. Anakinra within 1 week of baseline.
4. Other biological agents such as tocilizumab, etc. within 4 weeks of baseline.
19. Safety laboratory abnormality as any one of below
1. Aspartate transferase (AST), alanine aminotransferase (ALT) \> 1.5 x ULN at screening, unless deemed due to active myositis by investigator, in which case CK is also abnormally elevated and the ratio of AST or ALT by CK levels (adjusted as x ULN) should be \< 2.0 and gamma-glutamyl transferase \< 2.0 x ULN.
2. Bilirubin \> 1.5 x ULN at screening
3. Creatinine clearance \<30 mL/min calculated by Cockcroft-Gault formula at screening.
4. Hgb \< 9.0
5. Platelet count \< 100,000/mm3
6. White blood cells \< 3000/mm3
\-
2. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
3. Women of childbearing potential\* not willing or able to use at least two highly effective methods of birth control.
1. For females of reproductive potential: use of highly effective contraception for at least 1 month before study drug administration and agreement to use such a method during study participation and for an additional 28 days after the end of study drug administration.
2. For males of reproductive potential\*\*: use of condoms or other methods to ensure effective contraception with a partner
Highly effective contraception examples are:
* An approved hormonal contraceptive such as oral contraceptives, emergency contraception used as directed, patches, implants, injections, rings, hormonally-impregnated intrauterine device (IUD), or nonhormonal IUD.
* Abstinence
* Condoms
* A woman is considered of childbearing potential, i.e. fertile, following menarche, and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, tubal occlusion, and bilateral oophorectomy.
* A man is considered permanently sterile if a vasectomy has been performed.
4. Severe lung disease is defined by the following within the last 6 months before the screening:
1. FVC ≤40 percent predicted
2. DLCO \<30% of percent predicted (corrected for Hb)
3. O2 requirement of ≥10 L at rest based on home oxygen prescription.
4. Patient listed for lung transplant or actively going through lung transplant evaluation.
5. Moderate to severe active muscle disease from myositis as per any one of the criteria:
1. Creatine kinase (CK) \> 2000 U/mL.
2. Moderate to severe dermatomyositis rashes as per investigator evaluation (if rash present)
3. Moderate to severe arthritis as per investigator evaluation
4. Moderate to severe muscle weakness as per Sit to Stand 30 seconds of \< 7.
6. History of or ongoing serious active, chronic, or recurrent infection within 4 weeks of screening
7. Significant Pulmonary Hypertension (PH) is defined by any of the following:
1. Current clinical diagnosis of moderate to severe PH or significant right heart failure.
2. History of echocardiographic evidence of significant right heart failure or moderate to severe PH (TR jet \>= 2.9 m/s and signs of right ventricle (RV) dysfunction; or TR jet \> 3.4; or an right ventricle systolic pressure (RVSP) \> 40-55 with evidence of RV strain or dysfunction; or RVSP \> 55 regardless.
3. History of right heart catheterization showing a cardiac index ≤ 2.2 l/min/m² or severity of pulmonary hypertension (mPAP) \>40 millimeters of mercury (mmHg) with a pulmonary capillary wedge pressure (PCWP) \<15mmHg
4. PH requiring oral, IV, or inhaled therapy (such as epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, sildenafil, and tadalafil).
8. Increased bleeding risk, defined by any of the following:
1. Patients who require
* Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, factor Xa inhibitors, low molecular weight heparin)
* High dose antiplatelet therapy (\>325mg acetylsalicylic acid or \>75mg clopidogrel).
2. History of hemorrhagic central nervous system (CNS) event within 12 months of screening.
3. Any of the following within 3 months of screening:
* Hemoptysis or hematuria
* Active gastrointestinal (GI) bleeding or active GI ulcers.
4. Coagulation parameters: International normalized ratio (INR) \>2, prolongation of prothrombin time (PT) and by \>1.5 x ULN at screening.
9. History of a thrombotic event (including stroke and transient ischemic attack) within 12 months of screening.
10. Severe Cardiovascular disease, any of the following:
1. Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 months of screening.
2. Myocardial infarction or unstable cardiac angina within 6 months of screening.
11. Patients with underlying chronic liver disease (Child-Pugh A, B, or C hepatic impairment).
12. Known hypersensitivity to the trial medication or its components (i.e. soya lecithin)
13. Other diseases that may interfere with testing procedures or in the judgment of the Investigator may interfere with trial participation (such as significant GI issues like irritable bowel syndrome, inflammatory bowel disease, recent abdominal surgery, diverticular disease), or significant other lung diseases (such as severe obstructive lung disease such as severe asthma or severe chronic obstructive pulmonary disease, etc.) or may put the patient at risk when participating in this trial.
14. Life expectancy for a disease other than ILD \< 2.5 years (Investigator assessment).
15. In the opinion of the investigator, any condition precluding participation and completion of the study, including active alcohol and drug abuse or patients not able to understand or follow trial procedures.
16. Other investigational therapy was received within 1 month or 6 half-lives (whichever was greater) before the screening visit.
17. Current treatment with nintedanib or pirfenidone (taken the drug within 3 months of randomization or history of intolerance/side effects)
18. Current or recent use of one or more of the following medications (See: SOC immunosuppression and washout under section 6.2 for details)
1. Cyclophosphamide within 3 months of baseline.
2. Anti-tumor necrosis factor (infliximab, golimumab, or certolizumab) within 8 weeks or adalimumab within 4 weeks, and etanercept within 2 weeks of baseline.
3. Anakinra within 1 week of baseline.
4. Other biological agents such as tocilizumab, etc. within 4 weeks of baseline.
19. Safety laboratory abnormality as any one of below
1. Aspartate transferase (AST), alanine aminotransferase (ALT) \> 1.5 x ULN at screening, unless deemed due to active myositis by investigator, in which case CK is also abnormally elevated and the ratio of AST or ALT by CK levels (adjusted as x ULN) should be \< 2.0 and gamma-glutamyl transferase \< 2.0 x ULN.
2. Bilirubin \> 1.5 x ULN at screening
3. Creatinine clearance \<30 mL/min calculated by Cockcroft-Gault formula at screening.
4. Hgb \< 9.0
5. Platelet count \< 100,000/mm3
6. White blood cells \< 3000/mm3
\-
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Sponsor Role
collaborator
Rohit Aggarwal, MD
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rohit Aggarwal, MD
Professor of Medicine
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rohit Aggarwal, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Site Status
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Site Status
National Jewish Health
Denver, Colorado, United States
Site Status
University of South Florida
Tampa, Florida, United States
Site Status
University of Chicago
Chicago, Illinois, United States
Site Status
University of Kansas Medical Center
Kansas City, Kansas, United States
Site Status
Columbia University Irving Medical Center
New York, New York, United States
Site Status
Northwell Health
New York, New York, United States
Site Status
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site Status
University of Utah Health Sciences Center
Salt Lake City, Utah, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.
Reference Type
BACKGROUND
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.
Reference Type
BACKGROUND
Wilfong EM, Aggarwal R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Ther Adv Musculoskelet Dis. 2021 Dec 9;13:1759720X211060907. doi: 10.1177/1759720X211060907. eCollection 2021.
Reference Type
BACKGROUND
Shen L, Yan Q, Chen X. Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients. Arch Rheumatol. 2019 Aug 26;35(2):180-188. doi: 10.46497/ArchRheumatol.2020.7381. eCollection 2020 Jun.
Reference Type
BACKGROUND
Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, Chen S, Wang X, Ye S. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016 Sep 12;6:33226. doi: 10.1038/srep33226.
Reference Type
BACKGROUND
Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V. Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. J Rheumatol. 2015 Nov;42(11):2168-71. doi: 10.3899/jrheum.141182. Epub 2015 Mar 1.
Reference Type
BACKGROUND
Liang J, Cao H, Yang Y, Ke Y, Yu Y, Sun C, Yue L, Lin J. Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Front Med (Lausanne). 2021 Feb 3;8:626953. doi: 10.3389/fmed.2021.626953. eCollection 2021.
Reference Type
BACKGROUND
Aggarwal R, Oddis CV, Sullivan DI, Moghadam-Kia S, Saygin D, Kass DJ, Koontz DC, Li P, Conoscenti CS, Olson AL; MINT investigators. Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease. BMC Pulm Med. 2024 Oct 30;24(1):544. doi: 10.1186/s12890-024-03314-0.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY22090061
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Belimumab in Idiopathic Inflammatory Myositis
NCT02347891
COMPLETED
PHASE2/PHASE3
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
NCT00533091
COMPLETED
PHASE1
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
NCT02573467
COMPLETED
PHASE3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786
RECRUITING
PHASE3
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796
RECRUITING
PHASE3
Cause, Development, and Progression of Stiff-Person Syndrome
NCT00030940
COMPLETED
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
NCT01813617
COMPLETED
Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)
NCT03857854
UNKNOWN
PHASE3
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750
NOT_YET_RECRUITING
PHASE1/PHASE2
Study of Pioglitazone in Sporadic Inclusion Body Myositis
NCT03440034
COMPLETED
PHASE1
Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
NCT02971683
COMPLETED
PHASE3
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
NCT07103746
NOT_YET_RECRUITING
PHASE2
Rituxmab Versus IL-6 in Treating ILD
NCT05963048
COMPLETED
PHASE2/PHASE3
Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
NCT04062019
UNKNOWN
PHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441
ENROLLING_BY_INVITATION
PHASE3
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
NCT00001261
COMPLETED
PHASE2
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
NCT00802815
COMPLETED
EARLY_PHASE1
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
NCT01824251
COMPLETED
PHASE3
Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis
NCT04976140
COMPLETED
PHASE1/PHASE2
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
NCT00106184
COMPLETED
PHASE2
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06958939
NOT_YET_RECRUITING
PHASE1
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
NCT05986162
UNKNOWN
PHASE1
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
NCT00443222
COMPLETED
PHASE2/PHASE3